Index spins out Medicxi Ventures

Medicxi Ventures debuted on Tuesday with a EUR 210 million ($227.9 million) fund that will focus on early stage life science investments in Europe. Medicxi comprises the life sciences team, funds and portfolio companies of Index Ventures, a formerly hybrid VC that will now focus solely on technology investments.

Medicxi's Medicxi Ventures 1 (MV1) will primarily follow the asset-centric approach that the firm's team pursued at Index Ventures Life Sciences. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the Johnson & Johnson-JJDC venture arm of Johnson & Johnson (NYSE:JNJ) invested in the fund. ...